Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Dottikon Es Holding AG    DESN1   CH0020739006

DOTTIKON ES HOLDING AG

(DESN1)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Dottikon Es : Condensed Half-Year Report 2019/20

11/29/2019 | 02:08am EST

2019/20 Condensed Half-Year Report

Dottikon ES Holding AG

2019/20 Condensed Half-Year Report Your Specialist for Hazardous Reactions.

2 DOTTIKON ES

Condensed Half-Year Report 2019/20

Content

Summary/Outlook

3

Group Financial Statements DOTTIKON ES Group

10

Consolidated Income Statements

11

Consolidated Balance Sheets

12

Consolidated Cash Flow Statements

13

Consolidated Statements of Changes in Equity

14

Notes

15

Investor Relations

16

This Half-Year Report 2019/20 in English includes only condensed financial information.

The comprehensive Half-Year Report 2019/20 is available in German.

3 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Dear Shareholder,

Herewith we present to you DOTTIKON ES Group's Condensed Half-Year Report 2019/20 for the period from April 1 to September 30, 2019.

Net sales in the first business half-year were CHF 77.9 million, up by around 38 percent compared to the previous-year period. The production output - net sales plus inventory changes in semi-finished and finished goods - also increased by around 38 percent to CHF 92.2 mil- lion. This is the result of broad-based growth distributed over various products and customers and was achieved despite ongoing geopolitical and economic uncertainties. The challenges of intermittent scale-up of processes with limited experience due to accelerated market approval processes and short-term raw materials supply bottlenecks due to the enforcement of more rigorous environmental regulations for Asian chemical producers, which had a significantly adverse impact on the previous-year period's results, are still ongoing. Net income was CHF 15.4 million compared to CHF 2.0 million in the previous-year period, which represents a significant increase.

The increase in production output compared to the previous-year period was in proportion with the course of business and led to a CHF 4 million increase in inventory in semi-finished and finished goods to CHF 14.3 million. The respective material expenses rose by 33.3 percent to CHF 23.2 million, which translates into a slightly lower material expenses share of

25.1 percent (previous-year period: 26.0 percent) in relation to the production output. Per- sonnel expenses rose by 5.0 percent to CHF 34.0 million, mainly due to higher salaries with almost the same number of staff. Together with higher capitalized own production due to

KEY FIGURES, APRIL-SEPTEMBER

CHF million (unaudited)

2018

2019

Changes

Net sales

56.6

77.9

37.7%

EBITDA

9.8

27.9

184.0%

EBITDA margin (in % of net sales)

17.4%

35.8%

EBIT

2.4

18.7

675.5%

EBIT margin (in % of net sales)

4.3%

24.0%

Net income

2.0

15.4

671.5%

Net income margin (in % of net sales)

3.5%

19.8%

Cash flow from operating activities

24.8

18.1

-27.2%

Employees (FTEs, six-month average)

596

595

-0.2%

4 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

intensified investment activities in the renewal and expansion of the infrastructure and additional development and production capacities, earnings before interest, taxes, depreciation, and amortization (EBITDA) were CHF 27.9 million, up 184 percent compared to the previous- year period, with an EBITDA margin of 35.8 percent (previous-year period: 17.4 percent). The main drivers for the increase in depreciation and amortization of CHF 1.8 million compared to the previous-year period was the putting into operation of the new lab building for research and development as well as quality management and of additional chemical manufacturing capacities as well as the revaluation related to debottlenecking investments. Earnings before interest and taxes (EBIT) were CHF 18.7 million, around seven times higher than in the previous -year period. Together with the financial result and income taxes, this resulted in net income of CHF 15.4 million (previous-year period: CHF 2.0 million). Cash flow from operating activities was CHF 18.1 million in the reporting period (previous-year period: CHF 24.8 mil- lion) due to higher working assets related to the upcoming growth. Cash and cash equivalents were CHF 38.7 million at the end of the reporting period (end of business year 2018/19: CHF 43.8 million). The equity ratio was a high 80 percent.

For the ongoing full business year 2019/20, we continue to expect net sales above the previous year's figure. The infrastructure and production plant expansion and buildup to address the ongoing product-related growth will be intensified further.

Global economic growth dimmed in the period under review. In light of the growing economic risks and subdued inflation, central banks have adjusted their monetary policies, lowered the key interest rates and continued their monetary expansion. Still, the employment situation in industrialized nations has improved further, albeit at a slower pace. Economic growth, on the other hand, has weakened against the background of intensified international trade conflicts, social turmoil, and geopolitical tension. Economic risks continue to rise: The combination of rising geopolitical conflicts with high debt, low interest rates and an increased willingness to realize moderate returns with high-risk financial investments is dangerous. Renewed financial

5 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

market turmoil is becoming increasingly likely. The demonstration and expansion of power in the tripolar world order continues with an economically confrontational United States, subversive Russia, and self-confident, ambivalent China, intensifying the current regionalization trend by means of nationalism and regional conflicts. As a result, unpredictability and uncertainty intensify. Values such as trust, reliability, and long-term consistency, as well as cultural and regional proximity become increasingly important.

Key volume growth and innovation drivers in the pharma market are the demographic trend, the accelerated market approval for generics, biosimilars, and novel drugs, the governments' efforts to lower drug prices, and the rise in demand in China, above all for cancer drugs, in combination with a favorable financing environment.

The global sales share of patent-protected drugs is around 60 percent and is set to grow 6 to 7 percent annually in the coming years, clearly a stronger growth rate than the 2 to 5 percent expected for generics. In developed pharma markets, the share of expenses for patent-protected drugs stands at over 75 percent. The demographic trend and the accelerated market approval for novel drugs in combination with a favorable financing environment are key innovation drivers. They ensure long-term pharma volume growth despite governmental efforts to contain excessive drug price hikes and curb health care costs. In addition to the United States with a total of 42 percent and the EU5 with 14 percent of the global market share, China with nearly 10 percent market share and above-average growth in the past is becoming increasingly important.

So far, the United States has tried to curb the rising health care costs by stepping up economic competition, primarily by applying accelerated market approvals for novel drugs in particular. The resulting competitive pressure has resulted in significant price concessions for generics and larger indications with broader drug base treatment opportunities through list price discounts to drug wholesalers. However, these discounts often remain within the strongly consolidated and intransparent US drug distribution chain and hardly ever reach the patients. This has focused public attention on the steep increase in drug list prices and

6 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

animated politicians to step up for more transparency regulation in pricing and price reduc- tions, but so far with very little success. Still, the ongoing activities are expected to have some disciplinary effect on pricing.

The central Chinese government has implemented various reforms, modernized hospitals and improved the health care sector in order to facilitate inexpensive access to health insurance and innovative drugs for the population. Amid these efforts, it has gradually improved the market access for international pharma companies over the last few years. As a result, the sales share of patent-protected drugs in the Chinese pharma market is expected to rise from currently 20 to 30 percent over the next five years. Forward integration is another declared objective of China's government. Clinical data for market approval collected in China and other regions of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) will now be mutually recognized. In 2018, 48 new drugs were approved in China, 9 of which were locally developed innovations. Around 75 percent of these new market approval applications in China were subject to accelerated approval procedures.

Due to the promising pharma market for new innovative drugs, low interest rates and a lack of investment alternatives, financing in the biotech sector remains favorable, and innovation remains high. In 2018, the Food and Drug Administration approved a record number of 59 new drugs, and for the coming five years, the market expects a total of 430 new market approvals. Oncology is and remains the largest and fastest-growing indication area and is, at the same time, the indication area with the highest activity rate where generics, biosimilars, and new market approvals will be competing for market shares.

The trend among western pharma and biotech companies to repatriate drug substance and drug product manufacturing from Asia to the West continues, mainly driven by concerns regarding supply, quality, intellectual property, intensified regulatory pressure, and rising costs. In addition, demand for chemical process and analytical method development, API manufacturing, the related services and documentation, and the respective outsourcing is on

7 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

the rise. Large pharmaceutical companies struggle with lower margins amid rising costs and a lack of innovation, while smaller biotechs often lack the resources and expertise to build their own process development and production capacities in addition to product development programs. Custom Development and Manufacturing Organizations (CDMO) play a vital role in rendering these services as well as in diversifying approval risks and quantity requirement volatility. CDMO are expected to be strategic partners with a long-term perspective, rather than opportunistic service providers. Reliability, an impeccable quality track record, and profound experience are key criteria in selecting a CDMO, as a change in CDMO is time- consuming and switching costs are high.

The main risks to the generally positive outlook for the pharma market are more intense geopolitical escalation or a renewed global financial crisis and unexpectedly fast interest rate hikes. In addition, results could be adversely affected by disruptions in the supply chain due to the closure of Asian chemical producers based on the enforcement of environmental regu- lation, early competitive pressure due to a large number of new market approvals in comparable indication areas, stricter drug price regulation, and the occurrence of unwanted side effects related to insufficient drug safety tests on the back of accelerated market approvals. Yet regardless of these risks, the development of the pharma market creates an interesting outlook for high-quality, technologically advanced and specialized exclusive synthesis pro- viders, especially in the field of API manufacturing. The global pharma pipeline is promising and full of innovation. Market approval processes have accelerated and competitive pressure is intensifying. Quality requirements continue to increase, resulting in longer cGMP sequences in chemical API synthesis, and foster higher manufacturing volume requirements. In combination with the increased repatriation and outsourcing of small molecule API production, the lack of process development and production expertise and capacities among biotech and pharmaceutical companies has already created initial bottlenecks in high-quality,techno-­ logically­ proficient chemical process development and API manufacturing capacities. This trend is set to accentuate further over the coming few years, as many CDMO have been shaken

8 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

amid changes of ownership and restructuring efforts, or, based on the experience over the last two decades, are not yet ready to make capital-intensive investments in high-quality development and production capacities.

In the current pharmaceutical environment, DOTTIKON ES is well positioned to capture the imminent growth potential. The corporate strategy - strategic partner and specialist for hazardous reactions - is reaffirmed: By using enabling technology, we develop and manufacture high-quality, demanding chemical products safely and efficiently. We collaborate closely with our customers and cultivate an integrated partnership. By applying our full development and manufacturing capabilities, we support our customers in the successful execution of their strategy. In doing so, we create more value for our customers than our competitors. We continue to focus on safety, reliability, high flexibility, and speed and are thus strengthening our position as strategic development and manufacturing partner and performance leader. The pharmaceutical market is and remains our main market with ongoing growth potential. In order to realize the expected product-related sales growth, we increase capacity utilization of existing plants with targeted debottlenecking investments. The planning for a raw material, intermediates, and API warehouse has been continued. In addition, the planning phase for the redimensioned chemical multipurpose production plant for APIs to secure long-term growth continues. At the same time, the initiated planning for additional chemical pilot plant and API drying capacities is being continued. Against this background, investments for the current full business-year 2019/20 will be high. In order to finance the capacity expansion plans, we are preparing to raise external financing in 2020. In order to ensure long-term growth, the independent Performance Chemicals project team develops new proprietary innovative products to satisfy currently unmet market needs outside the pharmaceutical market and to bring these products closer to market readiness.

Our one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent data and process

9 Summary/Outlook DOTTIKON ES Group

Condensed Half-Year Report 2019/20

documentation and customer communication. The safety culture created over the past 105 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This challenges, tightens or shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used, maintained and continuously expanded to design, develop and optimize chemical processes and technical manufacturing procedures for the scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.

For the ongoing full business year 2019/20, we continue to expect net sales above the previous year's figure. The infrastructure and production plant expansion and buildup to address the ongoing product-related growth will be intensified further.

Dottikon, November 21, 2019

Dr. Markus Blocher

Chairman of the Board of Directors

10

Condensed Half-Year Report 2019/20

Group Financial

Statements

DOTTIKON ES Group

11 Group Financial Statements DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Consolidated Income Statements

April-September CHF thousand and % (unaudited, condensed)

2018

%

2019

%

Net sales

56'604

100.0

77'933

100.0

Changes in semi-finished and finished goods

10'325

14'298

Other operating income

2'339

2'752

Material expenses

-17'392

-23'182

Personnel expenses

-32'405

-34'014

Other operating expenses

-9'642

-9'872

Operating result before depreciation

and amortization (EBITDA)

9'829

17.4

27'915

35.8

Depreciation and amortization

-7'417

-9'209

Operating result (EBIT)

2'412

4.3

18'706

24.0

Financial income

468

253

Financial expenses

-560

-186

Financial result

-92

67

Result from associated companies

0

0

Net income before taxes

2'320

4.1

18'773

24.1

Income taxes

-319

-3'335

Net income

2'001

3.5

15'438

19.8

Basic/diluted earnings per share in CHF

1.60

12.33

Weighted average number of shares

1'250'884

1'252'148

12 Group Financial Statements DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Consolidated Balance Sheets

CHF thousand and % (unaudited, condensed)

31.03.2019

%

30.09.2019

%

Cash and cash equivalents

43'833

38'724

Current financial assets

0

0

Trade receivables

41'202

41'749

Other receivables

1'541

2'229

Inventories

67'088

76'601

Prepaid expenses and accrued income

1'198

1'892

Current assets

154'862

33.4

161'195

33.5

Property, plant and equipment

263'963

275'649

Intangible assets

729

678

Investments in associated companies

1'253

1'253

Assets from employer contribution reserve

42'284

42'284

Non-current assets

308'229

66.6

319'864

66.5

Assets

463'091

100.0

481'059

100.0

Trade payables

12'751

12'531

Income tax liabilities

1'276

4'474

Other current liabilities

17'588

19'842

Current provisions

50

49

Accrued expenses and deferred income

26'545

23'057

Current liabilities

58'210

12.6

59'953

12.5

Non-current provisions

5'420

5'420

Deferred tax liabilities

31'121

31'258

Non-current liabilities

36'541

7.9

36'678

7.6

Liabilities

94'751

20.5

96'631

20.1

Share capital

127

127

Share premium

61'826

62'158

Retained earnings

310'744

326'224

Own shares

-4'357

-4'081

Shareholders' equity

368'340

79.5

384'428

79.9

Shareholders' equity and liabilities

463'091

100.0

481'059

100.0

13 Group Financial Statements DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Consolidated Cash Flow Statements

April-September CHF thousand (unaudited, condensed)

2018

2019

Net income

2'001

15'438

Income taxes

319

3'335

Financial result

92

-67

Depreciation of property, plant and equipment

7'338

9'093

Amortization of intangible assets

79

116

Result from associated companies

0

0

Other non-cash income and expenses

-24

286

Interest received

21

3

Interest paid

-8

-7

Income taxes paid

-8

-10

Changes in

Trade receivables

29'938

-538

Other receivables as well as prepaid expenses and accrued income

-2'626

-1'263

Inventories

-11'220

-9'513

Trade payables

959

-1'000

Other current liabilities as well as accrued expenses and deferred income

-2'024

2'202

Provisions

-13

-1

Cash flow from operating activities

24'824

18'074

Outflows of

Current financial assets

0

0

Property, plant and equipment

-22'154

-23'028

Intangible assets

-238

-88

Inflows of

Current financial assets

0

0

Property, plant and equipment

0

19

Intangible assets

0

0

Cash flow from investing activities

-22'392

-23'097

Dividends paid

0

0

Purchase of own shares

0

0

Disposal of own shares

0

0

Cash flow from financing activities

0

0

Currency translation effect on cash and cash equivalents

-71

-86

Net change in cash and cash equivalents

2'361

-5'109

Cash and cash equivalents at the beginning of the reporting period

54'581

43'833

Cash and cash equivalents at the end of the reporting period

56'942

38'724

14 Group Financial Statements DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Consolidated Statements of Changes in Equity

CHF thousand (unaudited, condensed)

Share capital

Share premium

Changes in fair value of foreign exchange forwards

Other retained earnings

Own shares

Shareholders' equity

Balance 01.04.2018

127

61'358

37

294'470

-4'517

351'475

Net income

2'001

2'001

Changes of foreign exchange forwards

0

Income taxes on items recognized directly in equity

0

Dividends paid

0

Changes in own shares

468

160

628

Balance 30.09.2018

127

61'826

37

296'471

-4'357

354'104

Balance 01.04.2019

127

61'826

17

310'727

-4'357

368'340

Net income

15'438

15'438

Changes of foreign exchange forwards

52

52

Income taxes on items recognized directly in equity

-10

-10

Dividends paid

0

Changes in own shares

332

276

608

Balance 30.09.2019

127

62'158

59

326'165

-4'081

384'428

15 Notes DOTTIKON ES Group

Condensed Half-Year Report 2019/20

Notes to the Group Financial Statements of DOTTIKON ES Group (condensed)

1  SEGMENT REPORTING

DOTTIKON ES Group manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. DOTTIKON ES Group is specialized in hazardous reactions and positions itself as strategic devel­ opment and manufacturing partner and performance leader. DOTTIKON ES Group uses, maintains and continuously expands its versatile technology and equipment portfolio to design, develop and optimize chemical processes and technical manufacturing procedures for the scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.

According to Swiss GAAP FER 31 "Complementary Recommendation for Listed Public Companies", the reportable operating segments are determined using the segment reporting to the top management level for corporate management. DOTTIKON ES Group's top management level is the Board of Directors. In addition to its statutory tasks, the Board of Directors is responsible for the strategic focus and management of the Group. Strategic and important operational decisions of DOTTIKON ES Group are taken by the Board of Directors.

DOTTIKON ES Group builds on one single production site with the strategy of performance leadership as specialist for hazardous reactions. DOTTIKON ES Group mainly executes strongly heterogeneous projects with a focus on the exclusive synthesis of fine chemicals. Therefore, a differentiation in several operating segments is not informative.

The financial reporting to the Board of Directors is prepared in a single segment. DOTTIKON ES Group allocates resources and assesses their performance on entity level.

Therefore, the required information according to Swiss GAAP FER 31.8 "Segment Reporting" is shown in the consolidated interim financial statements.

2  SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

The consolidated interim financial statements were approved for issue by the Board of Directors on November 21, 2019. No significant events have occurred between September 30, 2019, and November 21, 2019, that would require an adjustment of the Group's carrying amounts of assets and liabilities or that would need to be disclosed under this heading.

16 DOTTIKON ESCondensed Half-Year Report 2019/20

Investor Relations

Issue Annual Report 2019/20

May 29, 2020

Annual General Meeting for the Business Year 2019/20

July 3, 2020

Issue Half-Year Report 2020/21

November 27, 2020

DOTTIKON ES HOLDING AG is listed on the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

Dottikon ES Holding AG

P.O. Box

5605 Dottikon

Switzerland

Tel +41 56 616 82 01

Fax +41 56 616 89 45

www.dottikon.com

Contact

Marlene Born, CFO investor-relations@dottikon.com

17 DOTTIKON ES

Condensed Half-Year Report 2019/20

DOTTIKON ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This challenges, tightens or shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used, maintained and continuously expanded to design, develop and optimize chemical processes and technical manufacturing procedures for the scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent data and process documentation and customer communication.

DISCLAIMER

Statements on future events or developments, particularly on the estimation of future business, reflect the view of the management of DOTTIKON ES HOLDING AG in the moment of composition. Since these naturally contain uncertainties and risks, they are given without guarantee and any liability is denied. DOTTIKON ES HOLDING AG refuses to actualize any forward-looking statements. The Internet version of these financial statements is exposed to fraudulent manipulation possibilities that are within such a medium, and is therefore without guarantee. The comprehensive Half-Year Report is available in German. Only the comprehensive German version submitted to the SIX Swiss Exchange is legally binding.

Dottikon ES Holding AG

P.O. Box, 5605 Dottikon, Switzerland, Tel +41 56 616 82 01, Fax +41 56 616 89 45, www.dottikon.com

Disclaimer

Dottikon ES Holding AG published this content on 29 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2019 07:07:04 UTC


© Publicnow 2019
All news about DOTTIKON ES HOLDING AG
11/27DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
11/26HALF-YEAR REPORT 2020/21 : Growth, Higher Profitability and Construction of New ..
PU
11/24DOTTIKON ES HOLDING AG : half-yearly earnings release
07/03DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
05/29DOTTIKON ES : Condensed Annual Report 2019/20
PU
05/29DOTTIKON ES : Higher Sales and Net Income – Investments in Further Growth
PU
05/26DOTTIKON ES HOLDING AG : annual earnings release
2019DOTTIKON ES : Markus Blocher Reorganizes Equity Interest Structure, Increases To..
PU
2019HALF-YEAR REPORT 2019/20 : Strong Growth and Significant Net Income Increase
PU
2019DOTTIKON ES : Condensed Half-Year Report 2019/20
PU
More news
Financials
Sales 2020 175 M 196 M 196 M
Net income 2020 33,2 M 37,2 M 37,2 M
Net cash 2020 42,8 M 48,1 M 48,1 M
P/E ratio 2020 2,43x
Yield 2020 -
Capitalization 241 M 271 M 271 M
EV / Sales 2019 0,08x
EV / Sales 2020 0,22x
Nbr of Employees 630
Free-Float 21,1%
Chart DOTTIKON ES HOLDING AG
Duration : Period :
Dottikon Es Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DOTTIKON ES HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers
NameTitle
Markus Blocher Chairman, Chief Executive Officer & MD
Marlene Born Chief Financial Officer
Urs Brändli Head-Processes & Technologies
Alfred Scheidegger Non-Executive Director
Stephan Kirschbaum Head-Business Development
Sector and Competitors
1st jan.Capitalization (M$)
DOTTIKON ES HOLDING AG224.92%271
MERCK KGAA28.33%71 018
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD103.99%20 446
KYOWA KIRIN CO., LTD.11.39%14 808
BETTA PHARMACEUTICALS CO., LTD.47.90%5 673
YUHAN CORPORATION38.48%3 515